ANDA 209525/S-001

CHANGES BEING EFFECTED IN 30 DAYS
APPROVAL

Teva Pharmaceuticals USA Inc
400 Interpace Parkway
Building A
Parsippany, NJ 07054
Attention: Elisabeth Gray
Director, Regulatory Affairs, Us Generics

Dear Madam:

This letter is in reference to your supplemental abbreviated new drug application (sANDA) received for review on November 17, 2021, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Icosapent Ethyl Capsules, 500 mg and 1 g.

The sANDA, submitted as “Changes Being Effected in 30 Days," provides for:

Additional site for drug product packaging

We have completed the review of this sANDA and it is **approved**.

REPORTING REQUIREMENTS

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98 and at section 506I of the FD&C Act. The Agency should be advised of any change in the marketing status of this drug or if this drug will not be available for sale after approval. In particular, under section 506I(b) of the FD&C Act, you are required to notify the Agency in writing within 180 days from the date of this letter if this drug will not be available for sale within 180 days from the date of approval. As part of such written notification, you must include (1) the identity of the drug by established name and proprietary name (if any); (2) the ANDA number; (3) the strength of the drug; (4) the date on which the drug will be available for sale, if known; and (5) the reason for not marketing the drug after approval.

If your product is a combination product as defined by 21 CFR 3.2(e) and is comprised of drug and device constituent parts we remind you that you must comply with the postmarking safety reporting requirements for an approved combination product (21 CFR Part 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products

ANNUAL FACILITY FEES

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions[1] with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1st of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the *Federal Register* notice announcing facility fee amounts.

All finished dosage forms or active pharmaceutical ingredients manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

If you have further questions regarding this supplement, you may contact Adlaide Addo, Regulatory Business Process Manager, at (301) 796 - 6923.

Sincerely yours,

{See appended electronic signature page}

For:
Paul Schwartz, Ph.D.
Director, Division of Post Marketing Activities II
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

[1] Some of these provisions were amended by the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Public Law 115-52, Title III).

Niles Ron

Digitally signed by Niles Ron
Date: 4/19/2022 01:31:44PM
GUID: 508da7030002882ddca5597dd1e581a7